PowderJect Completes Acquisition Of Medeva Vaccines

PowderJect Pharmaceuticals PLC has announced that following authorization by its shareholders at the company’s Extraordinary General Meeting on Friday September 29, it has completed its acquisition of Medeva’s vaccines business from Celltech Group Plc. The acquisition includes a range of marketed vaccines, which will be sold under the established Evans Vaccines brand, and one of Read more about PowderJect Completes Acquisition Of Medeva Vaccines[…]

(R)-Fluoxetine License Agreement To Become Effective

Sepracor Inc. has announced that the Federal Trade Commission (FTC) has closed its investigation, under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, of the license agreement that allows Eli Lilly and Company to exclusively develop and globally commercialize (R) – fluoxetine. (R)-Fluoxetine, a new chemical entity, is a modified form of an active ingredient found in Read more about (R)-Fluoxetine License Agreement To Become Effective[…]